Thermo Fisher Scientific Inc.

TMO Healthcare Diagnostics & Research

Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024. In the quarter to June 2026, revenue grew 10.5%, EPS grew 9.35%, free cash flow grew 51.8% and total debt rose 18.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.

690.00 6.49 −0.93%
Market cap
$257.5B
P/E
37.1×
Fwd P/E
23.7×
Dividend yield
0.27%
F-score
5/9
Altman Z
3.84
Beneish M
−2.46
Dividend safety
88/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

8 5 4 4
ROE
13.14% 13.02% 13.52% 13.51%
ROA
6.46% 6.46% 6.45% 6.50%
ROIC
5.92% 6.12% 5.56% 5.80%
Return on Tangible Assets
37.36% 27.84% 37.31% 36.57%
Average Days of Receivables
74.37 72.91 74.33 74.45
Free Cash Flow per Share
16.26 16.81 18.25 19.84
Free Cash Flow
6,145.00 6,337.00 6,789.00 7,362.00
Other line items

Show all line items

Columns are period end dates